Screening for oral cavity cancer in smokers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This project aims to improve early detection of oral cavity cancers among tobacco users aged 30-75 in the Somme region of France, where the incidence of such cancers is notably high. The study involves educating general practitioners about early detection and incentivizing screening through local tobacconists who distribute flyers with cigarette purchases. General practitioners will conduct screening examinations and collect data for evaluation. The initiative seeks to address the late-stage diagnosis of oral cancers, which is prevalent in this population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Any smoker who buys a pack of cigarettes over a period of two weeks in a tobacco shop located on the territory of the Somme
* lives in somme departement

Exclusion Criteria:

\-

Where it's running

• Amiens University Hospital
  Amiens, Picardie, France Recruiting
• Amiens University Hospital
  Amiens, Picardie, France Recruiting

Study contacts

• Principal investigator: Bernard DEVAUCHELLE, MD, phD — Amiens University Hospital
• Study coordinator: Bernard DEVAUCHELLE, MD, phD
• Email: devauchelle.bernard@chu-amiens.fr
• Phone: 033 3 22 66 83 25

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biomarkers for oral cavity cancer response to neoadjuvant immunotherapy using patient-specific tumor cultures

  This will test whether a patient-specific tumor culture can predict how people with oral cavity cancer respond to pembrolizumab given before surgery.

  Recruiting University of Wisconsin, Madison · Madison, Wisconsin · NCT07343596

• Neoadjuvant chemoimmunotherapy with PD-1 blockade to reduce surgery for advanced head and neck cancer

  This approach will try a short course of chemotherapy plus the PD-1 drug toripalimab before standard treatment for people with advanced head and neck cancers to shrink tumors and allow less extensive surgery or radiation.

  Recruiting Phase 2 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland · NCT07209189

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• Comparing navigation support to standard care for starting radiation therapy in head and neck cancer patients

  This study is testing a new support program to help people with head and neck cancer start their radiation therapy on time compared to the usual care they receive.

  Recruiting at 4 sites Medical University of South Carolina · St Louis, Missouri and 3 other locations · NCT05793151

• New surgical procedure for reconstructing the oral cavity and oropharynx in cancer patients

  This study is testing a new surgical method using a special tissue flap to see if it can safely help cancer patients who need reconstruction in their mouth and throat areas.

  Recruiting at 2 sites Institut Claudius Regaud · Montpellier and 3 other locations · NCT05757817

• Comparing methods for closing the radial forearm donor site after surgery

  This study is testing two different ways to close the arm after surgery for head and neck reconstruction to see which method helps patients heal better and feel happier with their results.

  Recruiting University of British Columbia · Vancouver, British Columbia · NCT05740033

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.